Vatter H - Search Results

1

Rapid closure technique in decompressive craniectomy.

Güresir E, Vatter H, Schuss P, Oszvald A, Raabe A, Seifert V, Beck J. Güresir E, et al. Among authors: vatter h. J Neurosurg. 2011 Apr;114(4):954-60. doi: 10.3171/2009.12.JNS091065. Epub 2010 Jan 29. J Neurosurg. 2011. PMID: 20113157

2

Reversal of tissue hypoxia by a single intraventricular dose of sodium nitroprusside in a patient with severe medically refractory cerebral vasospasm after subarachnoid haemorrhage.

Raabe A, Vatter H, Zimmermann M, Seifert V. Raabe A, et al. Among authors: vatter h. J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):123-4. doi: 10.1136/jnnp.72.1.123. J Neurol Neurosurg Psychiatry. 2002. PMID: 11784842 Free PMC article. No abstract available.

3

Endothelin-converting enzyme activity in human cerebral circulation.

Vatter H, Mursch K, Zimmermann M, Zilliken P, Kolenda H, Seifert V, Schilling L. Vatter H, et al. Neurosurgery. 2002 Aug;51(2):445-51; discussion 451-2. Neurosurgery. 2002. PMID: 12182783

4

Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery.

Vatter H, Zimmermann M, Jung C, Weyrauch E, Lang J, Seifert V. Vatter H, et al. Clin Sci (Lond). 2002 Aug;103 Suppl 48:408S-413S. doi: 10.1042/CS103S408S. Clin Sci (Lond). 2002. PMID: 12193134

5

Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction in isolated rat basilar artery.

Zimmermann M, Jung CS, Vatter H, Raabe A, Seifert V. Zimmermann M, et al. Among authors: vatter h. Acta Neurochir (Wien). 2002 Nov;144(11):1213-9. doi: 10.1007/s00701-002-1000-z. Acta Neurochir (Wien). 2002. PMID: 12434178

6

Cerebrovascular characterization of the novel nonpeptide endothelin-A receptor antagonist LU 208075.

Vatter H, Zimmermann M, Weyrauch E, Lange BN, Setzer M, Raabe A, Seifert V. Vatter H, et al. Clin Neuropharmacol. 2003 Mar-Apr;26(2):73-83. doi: 10.1097/00002826-200303000-00006. Clin Neuropharmacol. 2003. PMID: 12671526

7

[D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.

Zimmermann M, Jung CS, Vatter H, Raabe A, Seifert V. Zimmermann M, et al. Among authors: vatter h. Neurosurg Rev. 2003 May;26(2):125-32. doi: 10.1007/s10143-002-0242-9. Epub 2002 Nov 19. Neurosurg Rev. 2003. PMID: 12962299

8

Experimental approaches to evaluate endothelin-A receptor antagonists.

Vatter H, Zimmermann M, Seifert V, Schilling L. Vatter H, et al. Methods Find Exp Clin Pharmacol. 2004 May;26(4):277-86. Methods Find Exp Clin Pharmacol. 2004. PMID: 15319806

9

Characterization of the potent combined endothelin(A/B)-antagonist PD 142893 on cerebral vessels.

Zimmermann M, Vatter H, Weyrauch E, Lange BN, Krishnan R, Raabe A, Seifert V. Zimmermann M, et al. Among authors: vatter h. Neurol Res. 2004 Sep;26(6):692-7. doi: 10.1179/016164104225015967. Neurol Res. 2004. PMID: 15327761

10

Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction.

Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V. Vatter H, et al. J Neurosurg. 2005 Jun;102(6):1101-7. doi: 10.3171/jns.2005.102.6.1101. J Neurosurg. 2005. PMID: 16028770

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters